PSA Screening Reduces Prostate Cancer Deaths but Increases Overdiagnosis: Cochrane Review

Prostate-specific antigen (PSA) screening for prostate cancer remains a complex clinical decision, as updated evidence from the Cochrane Library indicates that while testing may reduce prostate cancer-specific mortality, it also increases the risk of overdiagnosis and potential harm from unnecessary subsequent interventions for men aged 45 to 80.

  • Mortality Impact: Routine PSA screening shows a high probability of reducing deaths specifically caused by prostate cancer, though its effect on overall, all-cause mortality remains less certain.
  • The Overdiagnosis Risk: Screening significantly increases the number of men diagnosed with localized prostate cancer, which includes cases that might never have progressed to cause clinical symptoms or mortality.
  • Emerging Diagnostics: Newer approaches combining PSA testing with kallikrein panels and MRI imaging are currently under evaluation; while these methods may detect more cancers, their long-term impact on survival rates is not yet established.

Cochrane Review Finds Fewer Prostate Cancer Deaths per 1,000 Screened

The updated Cochrane Library review, which synthesized data from six randomized controlled trials involving 789,086 participants across North America and Europe, highlights a nuanced reality for asymptomatic men.

Published in November 2025, the analysis suggests that for every 1,000 men screened, there is a reduction of two prostate cancer-specific deaths over a follow-up period reaching up to 23 years. This finding is largely driven by data from the European Randomized Study of Screening for Prostate Cancer (ERSPC).

While the reduction in cancer-specific mortality is statistically significant, the impact on all-cause mortality is less definitive. The analysis indicates that screening may lead to five fewer deaths per 1,000 men, but the confidence intervals remain broad enough that the effect could be negligible.

Researchers note that the clinical benefit must be weighed against the high probability of detecting “indolent” tumors—cancers that are slow-growing and would not have impacted a patient’s lifespan had they remained undetected.

Biopsy Carries Risks; Screening Detects More Early-Stage Cancer

The transition from a high PSA reading to a clinical diagnosis typically involves a prostate biopsy. This procedure, while essential for confirmation, carries inherent risks including infection, hematuria, and discomfort. The Cochrane review emphasizes that while screening successfully identifies more cases of localized, early-stage cancer, it does not necessarily show a substantial difference in the detection of advanced (Stage III or IV) prostate cancer.

Outcome Measure Screening Effect (per 1,000 men) Confidence Interval
Prostate Cancer Deaths 2 fewer 1 to 3 fewer
All-Cause Mortality 5 fewer 0 to 15 fewer
Localized Cancer Diagnosis 34 more N/A
Metastatic Cancer Diagnosis 5 fewer N/A

Screening Not Recommended for Men with Limited Life Expectancy

PSA screening is not a universal recommendation and should be discussed within the context of shared decision-making. Men with a limited life expectancy or those with significant comorbidities—conditions that would make aggressive treatment for prostate cancer risky—may not benefit from screening.

Professional medical consultation is warranted if a patient experiences persistent urinary symptoms, such as nocturia, weak stream, or hematuria, which require a physical examination, including a digital rectal exam (DRE), regardless of PSA status.

The integration of advanced biomarkers, such as the kallikrein panel, and multi-parametric MRI (mpMRI) aims to reduce the “false-positive” rate—where a high PSA leads to a biopsy that reveals no cancer or low-risk disease.

However, the current evidence base warns that these newer diagnostic combinations have not yet proven their ability to reduce mortality compared to standard diagnostic pathways. The Cochrane review was conducted without external commercial funding, ensuring that the synthesis of evidence remains independent of the diagnostic industry.

The question of how to best balance the detection of lethal cancers against the burden of over-treatment remains the primary challenge for public health authorities. Ongoing long-term studies continue to track whether newer imaging technologies will eventually provide a clearer survival advantage for the general population.

Photo of author

Health Desk

Health Desk at Archyde.

Canadian Tourist Films 93 Lei Hot Dog at Budapest Christmas Market

Astronomers Confirm Asteroid 2026 QQ8 as Temporary Mini-Moon Since April